Creative Biolabs offers a comprehensive suite of immuno-oncology assay services designed to support and accelerate your drug development pipeline from target validation to clinical trials. Recognizing the complexity of the tumor microenvironment and the multifaceted mechanisms of action of immunotherapies, we provide a diverse array of in vitro and in vivo assays to comprehensively evaluate the efficacy and safety of your novel agents. Our service offerings span key areas critical to successful immuno-oncology drug development:
- Target Engagement Assays: Evaluate the binding affinity and specificity of your therapeutic candidate to its target molecule, ensuring on-target activity and minimizing off-target effects.
- Mechanism of Action (MOA) Assays: Decipher the intricate mechanisms by which your immunotherapy exerts its anti-tumor effects, including immune cell activation, cytokine release, and tumor cell killing.
- Cell-Based Assays: Employ a wide range of cell-based assays, including cytotoxicity assays, proliferation assays, and mixed lymphocyte reactions (MLRs), to assess the functional activity of immune cells in response to your therapeutic.
- In Vivo Efficacy Studies: Utilize well-established in vivo models, including syngeneic tumor models and xenograft models, to evaluate the anti-tumor efficacy of your immunotherapy in a preclinical setting.
- Biomarker Analysis: Identify and validate predictive biomarkers that can stratify patient populations and guide clinical trial design, maximizing the chances of success.
Creative Biolabs emphasizes customized assay development, tailoring your approach to meet the specific needs of each project.Our team of experienced scientists provides expert guidance on assay selection, optimization, and data interpretation, ensuring reliable and actionable results. By partnering with Creative Biolabs, you gain access to cutting-edge technologies, comprehensive expertise, and a commitment to accelerating the development of innovative cancer immunotherapies.